Current practices using pembrolizumab and lenvatinib for advanced uterine cancer at a high-volume gynecologic oncology referral center in the Southeast (2116)

The phase III clinical trial Keynote-775 evaluating the use of lenvatinib plus pembrolizumab for advanced-stage uterine cancer showed longer progression-free survival (PFS) and overall survival (OS) compared with traditional chemotherapy. While encouraging, this trial has not been evaluated in a diverse population, and the regimen required frequent dose reductions due to toxicity. In clinical practice, many patients start at a lower than FDA-recommended dose, secondary to tolerability concerns. Also, only 4.1% of patients in Keynote-775 were Black, a population that is underrepresented in clinical trials and known to have worse outcomes. The objective of this study was to evaluate the combination of pembrolizumab and lenvatinib in a minority population at our institution and the outcomes using varying doses in a histologically high-risk population, including carcinosarcoma, which was not included in the trial.